Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

Advancing Care in Lupus Nephritis: Expert Perspectives on Current Practices and Future Directions in Italy.

Journal of clinical medicine·2026
Same author

Response to the Letter to the Editor entitled "Kidney Outcomes With Rituximab Versus Cyclophosphamide in Crescentic ANCA-Associated Glomerulonephritis: Contextualizing Observational Findings".

Kidney international reports·2026
Same author

Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study.

Rheumatology (Oxford, England)·2026
Same author

Pain, quality of life, work ability and psychosocial well-being in living kidney donors: A scoping review.

Nefrologia·2026
Same author

Chronic kidney disease trajectories in lupus nephritis: Is progression unavoidable?

Journal of autoimmunity·2026
Same journal

Renal Allograft Sympathetic Reinnervation and Possible Impact on Cardiovascular Risk Profile and Graft Function.

Kidney international reports·2026
Same journal

Randomized Crossover Trial of Low Sodium Dialysate on Tissue Sodium Accumulation in Hemodialysis.

Kidney international reports·2026
Same journal

Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria.

Kidney international reports·2026
Same journal

Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.

Kidney international reports·2026
Same journal

Association of IgG N-Glycans With Adverse Outcomes in CKD.

Kidney international reports·2026
Same journal

Urinary Soluble CD163: A Dynamic Biomarker for Monitoring Treatment Response and Relapse in IgA Nephropathy.

Kidney international reports·2026
See all related articles

Related Experiment Video

Updated: Jul 13, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.5K

Changing Phenotypes and Clinical Outcomes Over Time in Microscopic Polyangiitis.

Martina Uzzo1,2, Umberto Maggiore3, Filippo Sala1,4

  • 1Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Kidney International Reports
|October 18, 2023
PubMed
Summary
This summary is machine-generated.

Microscopic polyangiitis (MPA) patients diagnosed more recently show less severe kidney disease and a reduced risk of end-stage kidney disease (ESKD). However, the risk of MPA relapse has increased, while the risk of death remains comparable.

Keywords:
antineutrophil cytoplasmic autoantibodycrescentic glomerulonephritisdeathend-stage renal diseasemicroscopic polyangiitisvasculitis

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.1K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.0K

Related Experiment Videos

Last Updated: Jul 13, 2025

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

11.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.1K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.0K

Area of Science:

  • Nephrology
  • Rheumatology
  • Internal Medicine

Background:

  • Diagnosis and management of microscopic polyangiitis (MPA) have evolved.
  • It remains unclear if clinical presentation, histological findings, and patient/renal outcomes have changed over time.

Purpose of the Study:

  • To compare clinical and histopathological characteristics at diagnosis.
  • To assess changes in the risk of death, end-stage kidney disease (ESKD), and relapse rate in MPA patients over time.

Main Methods:

  • Retrospective analysis of 187 MPA patients diagnosed between 1980-2022, divided into two periods: 1980-2001 and 2002-2022.
  • Comparison of clinical and histopathological features, mortality, ESKD risk, and relapse rates using statistical models including Kaplan-Meier, Cox-regression, Aalen-Johansen, and Fine-Gray regression.

Main Results:

  • Patients diagnosed between 2002-2022 were older, had better kidney function (higher eGFR), and lower prevalence of severe sclerotic lesions compared to 1980-2001.
  • The risk of ESKD significantly decreased in the later period (HR 0.30, P < 0.001), with results sustained after adjustments.
  • Relapse risk was numerically higher in the 2002-2022 period (HR 1.64, P = 0.075), while patient survival was comparable between groups.

Conclusions:

  • MPA kidney involvement has become less severe over recent decades.
  • This has led to a reduced risk of ESKD but an increased relapse rate.
  • The risk of death associated with MPA has remained comparable across the studied periods.